Canadian wound-care product is being deployed in Ukraine, NanoTess says

Video: NanoTess-published frontline testimonial featuring Ukrainian military surgeon Dr. Vasyl Voronets. This is company-produced material and should be read as a testimonial, not independent clinical evidence. View the original video on YouTube.

Calgary-based NanoTess announced on Oct. 28 that its wound-care product NanoSALV Catalytic is being deployed in Ukraine through partners including the Public Health Centre of Ukraine and the Medical Forces and Sustainment Group East. The company said Medical Mercy Canada is also helping deliver humanitarian medical aid to civilians and that partner organizations have distributed the product to more than 6,000 people in Ukraine.

The announcement was made at the CAN Health Network’s annual conference. NanoTess describes the work as a response to difficult medical logistics in frontline, disaster-recovery and other austere settings, including areas where conflict has disrupted health services and supply routes. The release presents the deployment and distribution figures as company-reported information; Pharmasist has not independently audited the count or verified individual patient outcomes.

What is known about the product

NanoSALV Catalytic is listed in Health Canada’s Medical Devices Active Licence Listing under the name “NANOSALV CATALYTIC ADVANCED WOUND CARE TREATMENT MATRIX.” The listing identifies NanoTess Inc. as manufacturer, a Class II licence (No. 108236) and a first issue date of Sept. 2, 2022. A device licence is a regulatory status record; it is not, by itself, a comparison with other wound treatments or evidence that a product improves outcomes in every use setting.

NanoTess’s release describes its proprietary catalytic technology and quotes clinicians working in Ukraine. Those comments offer context about use in a challenging environment but are testimonials in a company announcement. The release does not report a controlled clinical study, patient-level outcome data, a comparator, or a formal evaluation of the drone-delivery model. The reported deployment is newsworthy, but it should not be presented as proof of superiority or as a change to wound-care standards.

Why the delivery model is notable

When roads, clinics and distribution networks are disrupted, compact medical supplies that can reach care teams by alternative routes may help address a logistics problem. The company describes NanoSALV as lightweight and suitable for drone delivery. The broader question for health systems is how supplies are selected, stored, replenished and integrated into local protocols—not simply whether a product can be transported. Those operational details were not fully described in the announcement.

Practice guidance for pharmacists

• When patients or colleagues ask about NanoSALV, separate the active Health Canada device licence from claims about comparative effectiveness, healing speed or outcomes. Check the authorized product information and intended use before discussing a specific clinical role.
• Treat distribution counts and frontline testimonials as company-reported unless independently evaluated data are available; do not turn them into a promise of benefit for an individual patient.
• Do not infer that a product is stocked, publicly covered or routinely orderable in a particular community from a nationwide availability statement. Confirm the supplier, current stock, applicable coverage and local procurement requirements.
• For serious burns, deep or complex wounds, suspected infection, or trauma, follow local emergency and wound-care pathways and seek appropriate assessment; a product announcement should never delay urgent care.
• If discussing the technology with a care team, ask what outcome measures, follow-up, adverse-event monitoring and independent evidence are available alongside the deployment report.

The development to watch is whether this deployment produces independently reported clinical and operational evidence, and whether the approach is adopted by additional health systems. For now, the confirmed regulatory fact is the device listing; the deployment scale and reported experience remain attributed to NanoTess and its partners.